13:30 – 14:00   PRE-CONFERENCE INDUSTRY SESSION

 Plenary Hall (Hall Ramblas A+B)

Boehringer Ingelheim: Early Action, Lasting Impact – Primary Care Providers Hold the Key
Per-Henrik Groop, University of Helsinki, Finland
Baruch Itzhak, Clalit Health Services, Israel

16:25 – 17:55   INDUSTRY SYMPOSIUM BY AstraZeneca

 Plenary Hall (Hall Ramblas A+B)

Chair: Baruch Itzhak, Clalit Health Services, Israel

16:25 – 16:55
Dapagliflozin as a disease modifying drug in Chronic Kidney
Disease
Ana Cebrián, Murcian Health Service, Spain

16:55 – 17:10
Dapagliflozin as a disease modifying drug in Cardiovascular
Disease
Mikhail Kosiborod, Saint Luke’s Health System, USA

17:10 – 17:25
Sustainability and Chronic Kidney Disease
Kumaran Krishnan, AstraZeneca, Switzerland

17:25 – 17:40
Making the Change for Kidney Health through policy change
AstraZeneca video

17:40 – 17:55
Q&A and Discussion

12:20 – 13:30   INDUSTRY SESSION

 Plenary Hall (Hall Ramblas A+B)

12:20 – 12:40    AstraZeneca: Our vision and pipeline in Cardiovascular, Renal & Metabolism
                           Elmas Malvolti, AstraZeneca, UK

12:40 – 13:00    Bayer: Finerenone in Practice – Bridging evidence and guidelines with clinical use
                          Ana Cebrián, Murcian Health Service, Spain

13:00 – 13:30    Novo Nordisk Israel:

                          Early therapy in type 2 diabetes
                          Avraham Karasik, Tel Aviv University, Israel

                          More Than Weight: Current Perspectives of Primary Care
                          Dan Oieru, Maccabi Health Services, Israel